SI2118128T1 - Fuzijski proteini, ki obsegajo tumorska zavrnitvena antigena NY-ESO-1 in LAGE-1 - Google Patents

Fuzijski proteini, ki obsegajo tumorska zavrnitvena antigena NY-ESO-1 in LAGE-1

Info

Publication number
SI2118128T1
SI2118128T1 SI200830870T SI200830870T SI2118128T1 SI 2118128 T1 SI2118128 T1 SI 2118128T1 SI 200830870 T SI200830870 T SI 200830870T SI 200830870 T SI200830870 T SI 200830870T SI 2118128 T1 SI2118128 T1 SI 2118128T1
Authority
SI
Slovenia
Prior art keywords
lage
eso
fusion proteins
tumor rejection
rejection antigens
Prior art date
Application number
SI200830870T
Other languages
English (en)
Slovenian (sl)
Inventor
Normand Blais
Martine Boyer
Vincent Brichard
Jamila Louahed
Denis Martin
Remi M. Palmantier
Clement Rioux
Original Assignee
Glaxosmithkline Biologicals S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0700759A external-priority patent/GB0700759D0/en
Priority claimed from GB0709707A external-priority patent/GB0709707D0/en
Application filed by Glaxosmithkline Biologicals S.A. filed Critical Glaxosmithkline Biologicals S.A.
Publication of SI2118128T1 publication Critical patent/SI2118128T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001188—NY-ESO
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
SI200830870T 2007-01-15 2008-01-11 Fuzijski proteini, ki obsegajo tumorska zavrnitvena antigena NY-ESO-1 in LAGE-1 SI2118128T1 (sl)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GB0700759A GB0700759D0 (en) 2007-01-15 2007-01-15 Novel fusion protein
US91492507P 2007-04-30 2007-04-30
US91484807P 2007-04-30 2007-04-30
GB0709707A GB0709707D0 (en) 2007-05-21 2007-05-21 Novel fusion protein
PCT/US2008/050879 WO2008089074A2 (en) 2007-01-15 2008-01-11 Fusion proteins comprising the tumor rejection antigens ny-eso-1 and lage-1
EP08727588A EP2118128B1 (en) 2007-01-15 2008-01-11 Fusion proteins comprising the tumor rejection antigens ny-eso-1 and lage-1

Publications (1)

Publication Number Publication Date
SI2118128T1 true SI2118128T1 (sl) 2013-02-28

Family

ID=41111108

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200830870T SI2118128T1 (sl) 2007-01-15 2008-01-11 Fuzijski proteini, ki obsegajo tumorska zavrnitvena antigena NY-ESO-1 in LAGE-1

Country Status (15)

Country Link
EP (1) EP2118128B1 (enExample)
JP (1) JP2010532656A (enExample)
KR (1) KR20090122426A (enExample)
BR (1) BRPI0806501A2 (enExample)
CA (1) CA2674458A1 (enExample)
DK (1) DK2118128T3 (enExample)
EA (1) EA016818B1 (enExample)
ES (1) ES2398492T3 (enExample)
HR (1) HRP20130022T1 (enExample)
MX (1) MX2009007572A (enExample)
PE (1) PE20081687A1 (enExample)
PL (1) PL2118128T3 (enExample)
SI (1) SI2118128T1 (enExample)
TW (1) TW200902049A (enExample)
WO (1) WO2008089074A2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008308474A (ja) * 2007-06-18 2008-12-25 Nitto Denko Corp 抗原ペプチド製剤の調製方法
BRPI1009873A2 (pt) 2009-03-17 2016-03-08 Glaxosmithkline Biolog Sa detecção aperfeiçoada de expressão gênica
GB0910046D0 (en) 2009-06-10 2009-07-22 Glaxosmithkline Biolog Sa Novel compositions
AU2012302778B2 (en) * 2011-08-31 2016-11-24 Mie University Vaccine preparation for cancer treatment
GB201116248D0 (en) 2011-09-20 2011-11-02 Glaxosmithkline Biolog Sa Liposome production using isopropanol
CN105555756B (zh) * 2013-06-28 2018-12-07 奥克兰联合服务有限公司 氨基酸缀合物和肽缀合物及缀合方法
EP3053592B1 (en) 2013-10-01 2025-04-23 Mie University T cell-inducing vaccine containing interepitope sequence promoting antigen presentation
CA2971677A1 (en) 2014-12-23 2016-06-30 Margaret Anne Brimble Amino acid and peptide conjugates and uses thereof
CN108697777A (zh) 2016-02-08 2018-10-23 国立大学法人三重大学 对免疫检查点抑制剂抵抗性肿瘤的t细胞输注疗法的预处理药物
TW201735952A (zh) 2016-02-26 2017-10-16 瑪格蕾特 安 布萊博 胺基酸及肽共軛物以及共軛過程
CA3119865A1 (en) * 2018-11-23 2020-05-28 Strike Pharma Ab Bi-specific conjugates

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06205672A (ja) * 1992-03-19 1994-07-26 Nippon Zeon Co Ltd 日本脳炎ウイルス及びｂ型肝炎ウイルスの表面抗原タンパク質の抗原部位を持つキメラタンパク質の製造法、およびそれに用いる組み換えバキュロウイルス
US6686147B1 (en) * 1998-07-15 2004-02-03 Ludwig Institute For Cancer Research Cancer associated antigens and uses therefor
US7060279B2 (en) * 2000-03-30 2006-06-13 Dendreon Corporation Compositions and methods for dendritic cell-based immunotherapy
US20030044813A1 (en) * 2001-03-30 2003-03-06 Old Lloyd J. Cancer-testis antigens
CA2551644C (en) * 2003-12-24 2014-03-04 Cerus Corporation Recombinant nucleic acid molecules encoding fusion proteins comprising antigens and bacterial secretory signal polypeptides, expression cassettes, and bacteria, and methods of usethereof
GB0409940D0 (en) * 2004-05-04 2004-06-09 Glaxosmithkline Biolog Sa Vaccine
BRPI0518933A2 (pt) * 2004-11-16 2008-12-16 Crucell Holland B V E Aeras Gl adenovÍrus recombinante defeituoso de replicaÇço, vetor de polinucleotÍdeo recombinante, vacina multivalente da tuberculose, e, uso do antÍgeno tb10.4 de mycobacterium
US20090186049A1 (en) * 2006-05-26 2009-07-23 Vincent Brichard Method of treating mage positive cancer
US20080187535A1 (en) * 2007-01-15 2008-08-07 Normand Blais Vaccine

Also Published As

Publication number Publication date
WO2008089074A3 (en) 2008-12-31
EA200900738A1 (ru) 2010-02-26
EA016818B1 (ru) 2012-07-30
HRP20130022T1 (hr) 2013-02-28
TW200902049A (en) 2009-01-16
CA2674458A1 (en) 2008-07-24
DK2118128T3 (da) 2013-02-18
KR20090122426A (ko) 2009-11-30
PL2118128T3 (pl) 2013-03-29
PE20081687A1 (es) 2008-12-25
ES2398492T3 (es) 2013-03-19
WO2008089074A9 (en) 2012-07-12
WO2008089074A2 (en) 2008-07-24
BRPI0806501A2 (pt) 2014-04-22
EP2118128B1 (en) 2012-11-07
JP2010532656A (ja) 2010-10-14
MX2009007572A (es) 2009-10-13
EP2118128A2 (en) 2009-11-18

Similar Documents

Publication Publication Date Title
PL2118128T3 (pl) Białka fuzyjne zawierające antygeny odrzucenia nowotworu NY-ESO-1 i LAGE-1
ZA201002160B (en) Human gm-csf antigen binding proteins
IL200610A0 (en) Human monoclonal anti-ip-10 antibodies and uses thereof
EP2069401A4 (en) MULTISPECIENT EPITOP BINDING PROTEINS AND THEIR USE
ZA201003759B (en) Antibodies against human nkg2d and uses thereof
IL204839A0 (en) Albumin fusion proteins
IL232008A (en) Protein isolate heterodimer alpha-4-in-cell-7-specific antigen-binding and various aspects thereof
IL217121A0 (en) Antimicrobial fusion proteins and uses thereof
IL200373A0 (en) Antibodies against erbb3 and uses thereof
IL200808A0 (en) Soluble il-17ra/rc fusion proteins and related methods
IL202128A0 (en) Immunoglobulin fusion proteins
LT2144924T (lt) Sulieto baltymo vakcina
HUS1800034I1 (hu) Anti-FGF23 ellenanyag és anti-FGF23 ellenanyagot tartalmazó gyógyászati készítmény
IL220752A0 (en) Tem8 peptides and vaccines comprising the same
IL200615A0 (en) Monoclonal human tumor-specific antibody
SI2510012T1 (sl) Protitelesa anti-C4.4A in njihova uporaba
ZA201001260B (en) Immunogenic polypeptides and monoclonal antibodies
ZA200901680B (en) Recombinant human interferon-like proteins
IL206334A0 (en) Sarp-i fusion proteins and their use
PT2118128E (pt) Proteínas de fusão compreendendo os antigénios de rejeição tumoral ny-eso-1 e lage-1
GB0700759D0 (en) Novel fusion protein
GB0713169D0 (en) Fusion proteins
PL380011A1 (pl) Nowe szkieletowe preparaty białkowe, sposób ich otrzymywania oraz zastosowania
GB0709707D0 (en) Novel fusion protein
GB0506945D0 (en) Human antibodies